Navigation Links
Ganeden Biotech Takes Sustenex(TM) National with GanedenBC30 Probiotic
Date:4/8/2008

hrough diet alone," said Ganeden Nutrition Advisor Susan Davis, MS RD. In terms of probiotic foods, Davis noted that yogurt stands out in consumers' minds. "Many people think they can get all the probiotics they need by eating yogurt, but they're wrong. The live, active cultures in yogurt struggle to make it though the harsh, acidic stomach environment. Probiotics like Bacillus coagulans found in Sustenex(TM) survive and successfully colonize the intestinal tract where they can do the most good," said Davis. "Just like Omega 3s and multi-vitamins, probiotics need to become part of our daily health regimen," Davis continued.

Recently, Dr. Mehmet Oz, M.D. and Dr. Michael Roizen, M.D., authors of the new book YOU: Staying Young, also outlined the importance of having beneficial bacteria in your gut for maintaining digestive and immune health. In YOU: Staying Young, Drs. Oz and Roizen listed a daily dose of 2 billion cells of the probiotic Bacillus coagulans as a choice to consider.

Sustenex

Sustenex(TM), is an all natural daily supplement developed by Ganeden Biotech, containing 2 billion cells of GanedenBC30, which is a patented strain of Bacillus coagulans. GanedenBC30 survives the hostile environment of the stomach, colonizes the intestines, and produces lactic acid, which are all critical components to the success of a probiotic.

"We plan to emphasize the uniqueness of the strain of Bacillus coagulans that we have identified and patented by branding it GanedenBC30 Probiotic," said Ganeden Biotech President Andy Lefkowitz. "The new brand logo will be visible on the Sustenex(TM) package as a clear identifier of our unique GanedenBC30 Probiotic. GanedenBC30 has powered our Digestive Advantage(TM) product line for consumers with particular digestive disorders. By placing it in Sustenex(TM), we're now offering the benefits of GanedenBC30 to consumers interested in probiotics as part of a daily health regimen," continued Lefkowitz.

Gane
'/>"/>

SOURCE Ganeden Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Ganeden Biotech Obtains Self-Affirmed GRAS Status for Probiotic Ingredient, GanedenBC30 (Bacillus coagulans GBI-30, 6086)
2. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
3. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
4. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
5. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
6. Finkelstein Thompson LLP Announces GPC Biotech AG Investigation
7. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
8. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
9. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
10. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
11. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... with State Biotech Leaders to Develop Blueprint ... Development while Boosting Rhode Island,s Growing Biotech ... R.I., Dec. 14 Several of ... medicine and biotechnology gathered today at Brown ... importance of medical innovation in Rhode Island ...
(Date:12/14/2009)... Scientific Corporation (NYSE: BSX ) today announced ... aggregate principal amount of its senior notes under the ... of $850 million of 4.50 percent notes due January ... 2020 and $300 million of 7.375 percent notes due ... net proceeds for general corporate purposes, including prepaying its ...
(Date:12/14/2009)... Dec. 14 Nektar Therapeutics (Nasdaq: ... been appointed to serve on its board of ... leader with over 35 years of experience in ... brings to Nektar extensive industry perspective at an ... W. Robin, President and CEO of Nektar and ...
(Date:12/14/2009)... completed the delivery of Brookfield Engineering’s Powder Flow Tester – ... with a smaller footprint and more compact design. , ... ... -- ThermoFab, a US-based thermoforming company, has completed the delivery ... from sheet metal to a plastic enclosure with a smaller ...
Breaking Biology Technology:Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 2Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 3Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 4Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3Dennis Winger Joins Nektar Therapeutics' Board of Directors 2Dennis Winger Joins Nektar Therapeutics' Board of Directors 3Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure 2
... Maxygen, Inc.,(Nasdaq: MAXY ), a biotechnology company ... that it will present at two,upcoming investor conferences. Russell ... Rodman and Renshaw 9th Annual Healthcare Conference Monday, ... 18th Annual Healthcare Conference Tuesday, November 6, 8:00 ...
... CAMBRIDGE, Mass., Oct. 25 Millennium,Pharmaceuticals, Inc. (Nasdaq: ... of a,conference call at 8:00 a.m. ET on ... Company,s third-quarter 2007 financial and,operational results and upcoming ... be available on the webcast. Prior to the,conference ...
... Submission Seeks Approval of Genasense in Relapsed/Refractory Patients, ... (Nasdaq: GNTA ) announced that the Company ... to Dr. Janet Woodcock, Acting,Director of the Center ... and Drug Administration (FDA). The appeal asks that ...
Other Biology Technology:Millennium to Webcast Third-Quarter 2007 Financial and Operational Results 2Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 2Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 3Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 4Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 5
(Date:12/16/2009)... of Maryland School of Medicine researcher will lead the ... prominent scientists in the field of stem cell research. ... Medicine, was chosen by the National Heart, Lung and ... consortium of national experts, which will be called the ... be funded by a $30 million grant over seven ...
(Date:12/16/2009)... Dec. 2 DigitalPersona, Inc., a ... today announced an agreement with IBM to ... biometric fingerprint technology on IBM SurePOS 500 ... allows point-of-sale applications to more easily and ... can be linked to the individuals who ...
(Date:12/16/2009)... -- IgeaCare Solutions Inc. is pleased to announce ... communications company previously operating as IgeaCare Systems Inc. ... forward under new leadership and funding. ,, IgeaCare ... the position of Chief Executive Officer. Under his ... a superior servicing and support model; fast and ...
Breaking Biology News(10 mins):University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium 2University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium 3DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems 2IgeaCare Solutions Inc. Emerges Under New Leadership and Funding 2Food Security to be the Top Issue for EUs Science Chief 62345 1Food Security to be the Top Issue for EUs Science Chief 62345 2Palatin Technologies Inc Issued U S Patent for Heart Failure Drug Candidate 15020 1Palatin Technologies Inc Issued U S Patent for Heart Failure Drug Candidate 15020 2Palatin Technologies Inc Issued U S Patent for Heart Failure Drug Candidate 15020 3Medicare Administrator Establishes Reimbursement Coding Policy for Agendias Breast Cancer Recurrence Test MammaPrint 28R 29 15018 1Medicare Administrator Establishes Reimbursement Coding Policy for Agendias Breast Cancer Recurrence Test MammaPrint 28R 29 15018 2
... drug warfarin to prevent harmful clotting after a heart attack, ... can vary greatly and can be hard to predict. Some ... gene involved in blood clotting, according to a new study ... Journal of Medicine. , By looking at the genetic makeup ...
... function of the microRNA mir1, Drs. Nicholas Sokol ... the expression profile, transcriptional regulation and loss-of-function phenotype ... conserved miRNA, whose expression in mouse and humans ... Strikingly, their study shows that, in Drosophila embryos, ...
... at the University of North Carolina Hospitals arrived in ... glowing track record in helping to repair heart valves, ... gastric bypass operations for morbid obesity. , The new ... System, manufactured by Intuitive Surgical. UNC currently is the ...
Other Biology News:Genetic variation alters response to common anti-clotting drug 2Genetic variation alters response to common anti-clotting drug 3Screen all at risk for HIV, plus pregnant women 2Screen all at risk for HIV, plus pregnant women 3
... CLS number is a new product ... product number. If showing no availability ... Sigma-Aldrich number (Z71,487-9) or contact customer ... centre neck 100 mm, No. of ...
... Blasticidin is a nucleoside ... It is a potent ... prokaryotic and eukaryotic cells. ... conferred by the products ...
... Aph-1a (Aph-1aL,S Loop 92-115), O2F1 Affinity ... a multiprotein complex consisting of presenilin, ... proteins are necessary for full proteolytic ... cleavage of a number of integral ...
... Glutathione-S-transferases (GSTs) are a group of enzymes ... xenobiotics in mammals. The enzymes protect cells ... of the glutathione to electrophilic xenobiotics, and ... and toxic effects of the compounds. GST ...
Biology Products: